AP2000001958A0 - Paroxetine 10-camphorsulfornate for treatment of CNS disorders. - Google Patents
Paroxetine 10-camphorsulfornate for treatment of CNS disorders.Info
- Publication number
- AP2000001958A0 AP2000001958A0 APAP/P/2000/001958A AP2000001958A AP2000001958A0 AP 2000001958 A0 AP2000001958 A0 AP 2000001958A0 AP 2000001958 A AP2000001958 A AP 2000001958A AP 2000001958 A0 AP2000001958 A0 AP 2000001958A0
- Authority
- AP
- ARIPO
- Prior art keywords
- paroxetine
- treatment
- camphorsulfornate
- cns disorders
- disorders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Paroxetine 10-camphorsulfonates are useful in the treatment of certain CNS disorders
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9808894.1A GB9808894D0 (en) | 1998-04-25 | 1998-04-25 | Novel compound |
PCT/GB1999/001246 WO1999055699A1 (en) | 1998-04-25 | 1999-04-23 | Paroxetine 10-camphorsulfonate for treatment of cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
AP2000001958A0 true AP2000001958A0 (en) | 2000-12-31 |
Family
ID=10831007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
APAP/P/2000/001958A AP2000001958A0 (en) | 1998-04-25 | 1999-04-23 | Paroxetine 10-camphorsulfornate for treatment of CNS disorders. |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1076659A1 (en) |
JP (1) | JP2002513020A (en) |
KR (1) | KR20010042929A (en) |
CN (1) | CN1306530A (en) |
AP (1) | AP2000001958A0 (en) |
AU (1) | AU3618699A (en) |
BG (1) | BG104973A (en) |
BR (1) | BR9909878A (en) |
CA (1) | CA2329913A1 (en) |
EA (1) | EA200001105A1 (en) |
GB (1) | GB9808894D0 (en) |
HU (1) | HUP0102298A2 (en) |
IL (1) | IL139018A0 (en) |
NO (1) | NO20005351D0 (en) |
PL (1) | PL343596A1 (en) |
SK (1) | SK15902000A3 (en) |
TR (1) | TR200003083T2 (en) |
WO (1) | WO1999055699A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100672184B1 (en) | 2004-09-21 | 2007-01-19 | 주식회사종근당 | Paroxetine cholate or cholic acid derivative salts |
CN104402708A (en) * | 2014-12-07 | 2015-03-11 | 河南领先科技药业有限公司 | Production method for sodium camphorate |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8430581D0 (en) * | 1984-12-04 | 1985-01-09 | Ferrosan As | Treatment |
EP0223403B1 (en) * | 1985-10-25 | 1993-08-04 | Beecham Group Plc | Piperidine derivative, its preparation, and its use as medicament |
HU221921B1 (en) * | 1996-07-08 | 2003-02-28 | Richter Gedeon Vegyészeti Gyár Rt. | N-benzyl-piperidine or tetrahydro-pyridine derivatives and processes for producing them |
-
1998
- 1998-04-25 GB GBGB9808894.1A patent/GB9808894D0/en not_active Ceased
-
1999
- 1999-04-23 CA CA002329913A patent/CA2329913A1/en not_active Abandoned
- 1999-04-23 SK SK1590-2000A patent/SK15902000A3/en unknown
- 1999-04-23 IL IL13901899A patent/IL139018A0/en unknown
- 1999-04-23 TR TR2000/03083T patent/TR200003083T2/en unknown
- 1999-04-23 WO PCT/GB1999/001246 patent/WO1999055699A1/en not_active Application Discontinuation
- 1999-04-23 EA EA200001105A patent/EA200001105A1/en unknown
- 1999-04-23 JP JP2000545859A patent/JP2002513020A/en active Pending
- 1999-04-23 CN CN99807798A patent/CN1306530A/en active Pending
- 1999-04-23 BR BR9909878-4A patent/BR9909878A/en not_active Application Discontinuation
- 1999-04-23 AP APAP/P/2000/001958A patent/AP2000001958A0/en unknown
- 1999-04-23 AU AU36186/99A patent/AU3618699A/en not_active Abandoned
- 1999-04-23 EP EP99918153A patent/EP1076659A1/en not_active Withdrawn
- 1999-04-23 HU HU0102298A patent/HUP0102298A2/en unknown
- 1999-04-23 KR KR1020007011750A patent/KR20010042929A/en not_active Application Discontinuation
- 1999-04-23 PL PL99343596A patent/PL343596A1/en not_active Application Discontinuation
-
2000
- 2000-10-24 NO NO20005351A patent/NO20005351D0/en not_active Application Discontinuation
- 2000-11-21 BG BG104973A patent/BG104973A/en unknown
Also Published As
Publication number | Publication date |
---|---|
TR200003083T2 (en) | 2001-02-21 |
BG104973A (en) | 2001-09-28 |
EA200001105A1 (en) | 2001-04-23 |
AU3618699A (en) | 1999-11-16 |
HUP0102298A2 (en) | 2002-05-29 |
EP1076659A1 (en) | 2001-02-21 |
NO20005351L (en) | 2000-10-24 |
BR9909878A (en) | 2000-12-26 |
WO1999055699A1 (en) | 1999-11-04 |
JP2002513020A (en) | 2002-05-08 |
SK15902000A3 (en) | 2001-05-10 |
KR20010042929A (en) | 2001-05-25 |
GB9808894D0 (en) | 1998-06-24 |
CA2329913A1 (en) | 1999-11-04 |
PL343596A1 (en) | 2001-08-27 |
IL139018A0 (en) | 2001-11-25 |
CN1306530A (en) | 2001-08-01 |
NO20005351D0 (en) | 2000-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04004714A (en) | Substituted aryl 1,4-pyrazine derivatives. | |
DK1143967T3 (en) | Anticonvulsant derivatives suitable for the treatment of Horton's headache | |
HK1039487A1 (en) | Process for the synthesis of azetidinones. | |
MY130489A (en) | Substituted aryl 1, 4-pyrazine derivatives | |
HUP0003964A2 (en) | Methods for treating thrombotic disorders | |
JO2410B1 (en) | Substituted 6-pyrido-pyrimidines | |
ZA200107689B (en) | 1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders. | |
MXPA01011923A (en) | Compositions and methods for treating cell proliferation disorders. | |
ID27214A (en) | TRIAZOLOPIRIDINA FOR TREATMENT OF TROMBOSIS DISORDERS | |
SG148840A1 (en) | Indole derivatives useful for the treatment of cns disorders | |
MY127675A (en) | Substituted 3-pyridyl-4-arylpyrroles, and related therapeutic and prophylactic methods | |
HK1039333A1 (en) | 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders | |
IL128028A0 (en) | Treatment of psychotic disorders | |
AP2000001958A0 (en) | Paroxetine 10-camphorsulfornate for treatment of CNS disorders. | |
AP2000001963A0 (en) | Paroxetine ascorbate. | |
NZ511997A (en) | Isonipecotamides for the treatment of integrin-mediated disorders | |
ZA200110539B (en) | Oxazinocarbazoles for the treatment of CNS diseases. | |
IL153605A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
IL139303A0 (en) | Treatment of arthritis and other similar conditions | |
IL153254A0 (en) | Indole derivatives useful for the treatment of cns disorders | |
EP1425020A4 (en) | Methods and compositions for treating apoptosis associated disorders | |
SI1049672T1 (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
UA32316A (en) | Method for treating pathologic climacteric | |
ZA994077B (en) | Intranasal formulations for treating sexual disorders. | |
MY125294A (en) | Anticonvulsant derivatives useful in treating chronic neurodegenerative disorders |